The company closes another year of consolidation and growth, driven by investment in
human capital, scientific innovation and a solid presence in the media. For 2026,
international expansion and a strengthening of its institutional role have been announced.
A path founded on a clear strategy that combines scientific rigour and an
entrepreneurial and ethical vision. Salugea, a company positioned in the high-end
nutraceuticals segment, closes the year just ended with results that confirm the solidity of the project:
a turnover that reaches 15 million euros, marking an increase of +31% on the previous year.
A result that is the fruit of a solid performance across all sales channels, online and offline, and that rewards the choice to give priority to quality, transparency and solidity of the development model. If the figures tell of economic success, it is the analysis of the key drivers that reveals the logic that has led the company to become an established point of reference for Italian pharmacists and consumers.
The human factor and product innovation as engines of development
At the heart of the Salugea model there has always been the valuing of people. The past year was marked by significant investment in human capital, with the addition of qualified, high-profile professionals. A precise choice: to raise internal know-how in order to respond competently to the challenges of a constantly evolving market.
At the same time, the company has accelerated on product innovation. The expansion of the product range with new launches in the Inner Beauty and Gastrointestinal Wellbeing areas did not represent a simple commercial extension, but a precise response to emerging health needs, addressed with 100% natural formulations with a high standardisation level, which together with the rigorous use of pharmaceutical-grade dark glass make it the distinctive trait of the company.
Visibility and consolidation of the network: an integrated strategy
The evolution of the brand's positioning has also come through a change of pace
in communication. Investments recorded a significant increase, covering the digital landscape and traditional media synergistically, with an integrated approach aimed at building an informed and aware relationship with the consumer.
On the commercial front, the structure has become even more widespread. The consolidation of the sales network and of Medical Scientific Information has enabled Salugea to strengthen the dialogue with the medical profession, translating into an expansion of distribution coverage, both through the direct network of agents and through the strengthening of partnerships with the main intermediate distributors and pharmacy chains.
2026: a new phase of development
For Salugea, 2026 marks the start of a new phase of evolution. Alongside
the maintenance of sustainable economic growth, the company aims to strengthen its institutional role, working with bodies, associations and industry stakeholders to promote a culture of wellbeing founded on prevention, information and scientific responsibility.
“We are working to build a company that is solid and recognisable over time, able to
grow while remaining consistent. The choices we are making today, from research
to organisation, are designed to support responsible development beyond
national borders.” Marco De Gregorio, Founder and CEO of Salugea.
The main lines of development for the new year include the strengthening of research and innovation activities, with particular attention to the development of advanced solutions based on scientific evidence and geared to health needs that are still poorly covered; continued investment in skills, in particular in the physical channel, in order to be ever closer to pharmacies and parapharmacies; and an approach to economic sustainability founded on targeted investments and on the pursuit of sound profitability.
A key step in 2026 will also be the opening up to foreign markets. The internationalisation process has begun and will lead Salugea to engage with a global dimension, through careful assessment of regulatory and cultural contexts. Exporting the Salugea model means taking beyond national borders not only products, but a system founded on transparency, ethics and respect for human physiology.
On these foundations, Salugea is preparing to face a new phase of evolution,
keeping its identity firm and strengthening its positioning as an
entrepreneurial organisation oriented towards long-term value.
19/01/2026 Corriere della Sera